Specialty Drug Trends: A Growing Concern for Payers
Executives from Prime Therapeutics discussed the future of specialty drugs at AMCP Nexus 2025, highlighting key areas such as autoimmune therapies, multiple sclerosis treatments, and emerging cell and gene therapy challenges.
A recent report from the Business Group on Health’s Employer Health Care Strategy Survey found that employers predict a 9% increase in healthcare costs for 2026, with specialty drugs being a major contributor to this rise.
One of the biggest cost drivers is cancer care, with the growing prevalence of cancer diagnoses and escalating costs leading to increased spending for the fourth year in a row.
- Over 1,000 novel drugs have been launched globally in the last 20 years.
- Almost 400 novel drugs have been launched in the past five years.
- In 2024, 48 novel drugs were launched in the United States, representing a 22% increase from the 2015 to 2019 period.
Specialty biologic drugs are expected to have a significant impact on spending, with payers bracing for the challenges ahead.
Specialty drugs continue to be at the top of many spending reports.
Author's summary: Payers prepare for rising specialty drug costs.
More News
- Linde Reports Third-Quarter 2025 Results
- MEG Delays Vote on $5.4B Oil Takeover Yet Again
- Bitches in Stitches: Northern Quarter's new all-female comedy shows - Mancunian Matters
- Cenovus announces third-quarter 2025 results
- ‘Tyrant’ teaser hints at Charlize Theron’s boldest role yet in Amazon’s intense thriller
- Samsung taps Nvidia GPUs for AI factory
- Ayuba Sylvester James: “For MCP to Rise, Chakwera Must Fall” - Malawi Nyasa Times - News from Malawi about Malawi
- 'America's Got Talent' competitors iLuminate to turn lights down, light dance moves up at the First Interstate Center for the Arts
- Best gaming monitor deal: Save $500 on Samsung 57-inch Odyssey Neo G9
- Tractor Trailer Crash North of Mansfield - Ozark Radio News